4SC

About:

4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases.

Twitter/X: 4sc_ag

Top Investors: Bayern Kapital, BionX™ Medical Technologies, Wellington Partners, BioM AG, Santo Holding

Description:

4SC discovers and develops targeted, small-molecule drugs for the treatment of cancer and autoimmune diseases in indications with high unmet medical needs. These drugs are intended to provide innovative treatment options that are more tolerable and efficacious, and provide a better quality of life.

Total Funding Amount:

94.7M EUR

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Planegg, Bayern, Germany

Founded Date:

1997-01-01

Contact Email:

ursula.herz(AT)4sc.com

Founders:

Number of Employees:

51-100

Last Funding Date:

2019-11-12

IPO Status:

Public

Industries: